PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $716,623 | -37.6% | 42,963 | +3.3% | 0.00% | 0.0% |
| Q2 2023 | $1,148,688 | -46.9% | 41,589 | -55.8% | 0.00% | -66.7% |
| Q1 2023 | $2,163,311 | +42.2% | 94,057 | -32.5% | 0.00% | +50.0% |
| Q4 2022 | $1,520,842 | +23.2% | 139,399 | -4.8% | 0.00% | 0.0% |
| Q3 2022 | $1,234,648 | +801.2% | 146,459 | +743.3% | 0.00% | – |
| Q2 2022 | $137,000 | -66.7% | 17,368 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $411,000 | -30.8% | 17,368 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $594,000 | +92.2% | 17,368 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $309,000 | -57.6% | 17,437 | +7.3% | 0.00% | 0.0% |
| Q2 2021 | $729,000 | +86.4% | 16,250 | +7.7% | 0.00% | 0.0% |
| Q1 2021 | $391,000 | +48.1% | 15,094 | +15.5% | 0.00% | 0.0% |
| Q4 2020 | $264,000 | +34.7% | 13,071 | +30.4% | 0.00% | – |
| Q3 2020 | $196,000 | – | 10,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |